{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Telix Pharmaceuticals Limited"},"Symbol":{"label":"Symbol","value":"TLX"},"Address":{"label":"Address","value":"55 FLEMINGTON,ROAD, NORTH MELBOURNE, 03051, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as \"theranostics\". We have an extensive pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Our theranostic approach is intended to use imaging and therapy together to \"see and treat\" cancer and rare diseases, to both better inform treatment decisions and deliver personalized therapy for patients."},"CompanyUrl":{"label":"Company Url","value":"www.telixpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}